These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25810989)

  • 21. Features of the metabolic syndrome in late adolescence are associated with impaired testicular function at 20 years of age.
    Hart RJ; Doherty DA; Mori TA; Adams LA; Huang RC; Minaee N; Handelsman DJ; McLachlan R; Norman RJ; Dickinson JE; Olynyk JK; Beilin LJ
    Hum Reprod; 2019 Mar; 34(3):389-402. PubMed ID: 30576537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
    Vanni E; Marengo A; Mezzabotta L; Bugianesi E
    Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk.
    Wieland AC; Mettler P; McDermott MT; Crane LA; Cicutto LC; Bambha KM
    J Clin Gastroenterol; 2015 Jan; 49(1):e6-e10. PubMed ID: 24440943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.
    Targher G; Byrne CD
    J Clin Endocrinol Metab; 2013 Feb; 98(2):483-95. PubMed ID: 23293330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
    Valenti L; Bugianesi E; Pajvani U; Targher G
    Liver Int; 2016 Nov; 36(11):1563-1579. PubMed ID: 27276701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 32. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis.
    Garcia-Martinez I; Alen R; Rada P; Valverde AM
    Front Med (Lausanne); 2020; 7():395. PubMed ID: 32850903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease as a multi-systemic disease.
    Fotbolcu H; Zorlu E
    World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.
    Saponaro C; Gaggini M; Gastaldelli A
    Curr Diab Rep; 2015 Jun; 15(6):607. PubMed ID: 25894944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus.
    Zhang Z; Wang J; Wang H
    Exp Ther Med; 2018 Mar; 15(3):2936-2940. PubMed ID: 29456698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic.
    Ismail MH
    Am J Med Sci; 2011 Jun; 341(6):485-92. PubMed ID: 21412139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical workup of fatty liver for the primary care provider.
    Jensen T; Wieland A; Cree-Green M; Nadeau K; Sullivan S
    Postgrad Med; 2019 Jan; 131(1):19-30. PubMed ID: 30496690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.